A 1-for-30 reverse split with authorized shares unchanged at 1.5 billion creates massive potential dilution (over 2,300% of post-split shares). Monitor for subsequent equity offerings or Nasdaq compliance updates.
KALA drugs
KALA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.1388entry
- T+1 · 20h ago −8.02%α −6.11% · $0.1277
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
KALA BIO filed a Certificate of Amendment to effect a 1-for-30 reverse stock split, reducing outstanding shares from 19,339,786 to approximately 644,659. The split becomes effective November 13, 2026, with split-adjusted trading starting November 16, 2026. The number of authorized shares remains unchanged at 1.5 billion.
Key Facts
- Reverse stock split at a 1-for-30 ratio, effective 4:05 p.m. on November 13, 2026.
- Outstanding shares reduced from 19,339,786 to approximately 644,659.
- Authorized shares remain unchanged at 1,500,000,000.
- Stockholders approved the split at the November 3, 2026 annual meeting, with the board setting the ratio.
- No fractional shares will be issued; cash payment in lieu based on November 12 closing price.
- Split-adjusted trading begins November 16, 2026 on Nasdaq under symbol KALA.
Financial Impact
Outstanding shares reduced from 19,339,786 to approximately 644,659; no change in authorized shares (1.5 billion).
Risk Factors
- The company retains 1.5 billion authorized shares post-split, enabling substantial future dilution.
- Reverse splits are often a signal of low stock price and potential delisting risk.
- No financial data or business update was provided in this filing.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-012313 |
| Document: kalabio_ex99-1.htm | 0001829126-26-012313 |
| Document: kalabio_ex3-1.htm | 0001829126-26-012313 |
| Document: 0001829126-26-012313-index-headers.html | 0001829126-26-012313 |
| Document: 0001829126-26-012313-index.html | 0001829126-26-012313 |
| Document: 0001829126-26-012313.txt | 0001829126-26-012313 |
Track record
10 reports on KALA
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +77.78% at T+60 after the Jun 26, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.1496 Now $0.1390 +7.09% settles Nov 17
- Nov 12, 20264d ago 8-K Bearish 5/10 Viewing Entry $0.1388 to $0.1277 Now $0.1390 −0.14% ▲ +8.02% +6.11% vs SPY
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1773 to $0.1710 Now $0.1390 −21.60% ▼ −3.55% −3.19% vs SPY
- Oct 19, 202628d ago SC 13G Neutral 3/10 Entry $0.1926 to $0.1897 Now $0.1390 −27.83% ▼ −1.51% −1.84% vs SPY
- Sep 24, 20267w ago Press Release Neutral 3/10 Entry $0.5600 to $0.4760 Now $0.1390 −75.18% ▼ −15.00% −15.54% vs SPY
- Aug 28, 202611w ago 8-K Bearish 8/10 Entry $0.6901 to $0.6727 Now $0.1390 +79.86% ▲ +2.52% +2.22% vs SPY
- Jul 22, 202616w ago 424B5 Bearish 8/10 Entry $0.6103 to $0.6342 Now $0.1390 +77.22% ▼ −3.92% −3.81% vs SPY
- Jun 26, 202620w ago EFFECT Bearish 7/10 Entry $2.52 to $2.09 Now $0.1390 +94.48% ▲ +17.06% +18.71% vs SPY
- May 7, 202627w ago S-3 Neutral 2/10 Entry $3.95 to $3.91 Now $0.1390 −96.48% ▼ −1.01% −1.24% vs SPY
- Mar 4, 202636w ago Press Release Mixed 6/10 Entry $17.25 to $0.2750 Now $0.1390 −99.19% ▼ −98.41% −97.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers